IPOX® Research Analyst Dr. Lukas Muehlbauer, offered his perspective on the upcoming US IPO of Ascentage Pharma, a Chinese biopharmaceutical firm targeting a valuation of $1.75 billion. Ascentage, backed by Takeda Pharmaceutical, is seeking a US listing after its shares have already been trading on the Hong Kong stock exchange since 2019.

IPOX® CEO Josef Schuster shared his insights on the upcoming IPO of Smithfield Foods, which aims for a valuation of up to $10.73 billion. The pork producer's return to the U.S. stock market after over a decade is one of the first major consumer IPOs of the year, potentially setting a precedent for other companies in the sector.

U.S. IPO activity is picking up with eToro's potential $5 billion+ and Klarna's possible $20 billion IPO. Titan America aims to raise over $500 million. In Asia, LG CNS priced its IPO at $823 million, and Guming Holdings targets $300 million in Hong Kong. Europe sees HBX Group's €725 million IPO. Riyad Capital's potential $2.5 billion IPO leads activity in MENA.

IPOX® CEO Josef Schuster spoke with Bloomberg about the expected rebound in US energy IPOs, driven by companies like Venture Global. Schuster noted rising commodity prices and recent IPO successes create a favorable environment, adding that the market is "ready for a slew of good energy IPOs."

IPO activity is picking up globally, with the US seeing filings from biotech firms like Maze and Metsera. Europe anticipates large listings from Stada and HBX Group, while Shein and Shawbrook consider London. In Asia, NTT plans a Singapore REIT IPO, and several Chinese firms eye Hong Kong, though CATL's faces US blacklisting concerns. LG CNS launched its IPO in South Korea, while K Bank canceled its attempt. Saudi Tabreed is planning a potential Riyadh IPO.

EG Group, a UK-based fuel station operator, is planning a U.S. IPO valued at over $16 billion. Ascentage Pharma seeks $100 million in a Nasdaq IPO for cancer treatments. Germany's IPO market anticipates growth in 2025 with major listings. Chery Auto aims for a $1 billion Hong Kong IPO, valuing it at $14 billion. Meanwhile, Hong Kong will see 8 IPOs raising $755 million by mid-January 2025, reflecting robust investor interest.

In recent IPO news, the US market sees Databricks potentially delaying its IPO post-funding, while FedEx explores options for its freight division. Shifting focus internationally, there's positive momentum as EV battery giant CATL considers a significant Hong Kong listing. Adding to the upbeat news, Greek multinational METLEN is advancing its multi-billion pound London IPO, showcasing confidence in European markets.

London's IPO market shows mixed signals with French streaming firm Canal+ planning a €5-6 billion listing, while facing challenges with Shein's delayed approval over supply chain concerns. In Asia, Orion Breweries prepares for a $200 million Tokyo listing, Foshan Haitian seeks a HK$1.5 billion Hong Kong dual listing, and Kioxia completed an $800 million IPO, though at a valuation significantly below its 2018 level.

Recent IPO announcements reflect strong global market activity across diverse sectors. Notable listings include Holcim's $30 billion North American spin-off, Seven & i's $6.6 billion 7-Eleven USA IPO, and ServiceTitan's $5.16 billion tech listing in the U.S. The MENA region sees healthcare and retail offerings from Almoosa Health and Nice One, while Asia-Pacific activity includes Kioxia's $727 million Tokyo listing and Mao Geping's $270 million Hong Kong debut.

IPOX® CEO Josef Schuster sat down with Chuck Jaffe on the Money Life with Chuck Jaffe podcast to discuss the state of the IPO market, its strong performance amid market highs, and the factors driving its momentum. Schuster highlighted the role of low interest rates, robust earnings, and the rise of sectors like AI and industrials in fueling IPO growth.

Josef Schuster, founder and CEO of IPOX Schuster LLC, was recently featured in Reuters, offering his perspective on the upcoming IPO of ServiceTitan, which aims for a valuation of up to $5.16 billion.